home / stock / obsv / obsv news

OBSV News and Press, ObsEva SA From 08/07/19

Stock Information
Company Name: ObsEva SA
Stock Symbol: OBSV
Market: NASDAQ
Website: obseva.com
Menu
OBSV OBSV Quote OBSV Short OBSV News OBSV Articles OBSV Message Board
Get OBSV Alerts

News, Short Squeeze, Breakout and More Instantly...
OBSV - ObsEva Reports Second Quarter 2019 Financial Results

  Multiple Major Milestones Expected This Year -    Q4:19 Phase 3 data for IMPLANT 4 trial of nolasiban   -    Nolasiban MAA submission targeted for year- end 2019 -    Q4:19 Phase 3 data for PRIMROSE 2 trial of linzagolix in uterine fibroids ...
OBSV - ObsEva SA Announces $75 Million Credit Facility with Oxford Finance LLC

  Geneva, Switzerland and Boston, MA – August 7, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s repro...

OBSV - ObsEva SA to Hold Second Quarter 2019 Financial Results and Business Update Call on August 7, 2019

  Geneva, Switzerland and Boston, MA – August 5, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s repro...

OBSV - ObsEva: Building A Top Tier Company Focused On Women's Health Issues

(Sourced from ObsEva Website) In a previous article I introduced my readers to a Swiss based biotech—Idorsia ( OTCPK:IDRSF ). With this article I wish to share another Swiss based company, where I think they also would make a great investment for one’s stock portfolio. The ...
OBSV - ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022

Geneva, Switzerland and Boston, MA – July 26, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive h...

OBSV - ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

Geneva, Switzerland and Boston, MA – July 18, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s re...

OBSV - ObsEva Hosts KOL Meeting on IVF Trends, Unmet Need and Market Potential of Nolasiban

                                         Company remains on track to submit Nolasiban MAA in the fourth quarter of 2019   GENEVA, Switzerland and BOSTON, MA - ...
OBSV - ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) July 17, 2019 in New York City

Geneva, Switzerland and Boston, MA – July 12, 2019 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and...

OBSV - ObsEva completes enrollment in late-stage study of linzagolix for heavy menstrual bleeding

ObsEva SA (NASDAQ: OBSV ) has  completed patient recruitment in its Phase 3 clinical trial PRIMROSE 1 evaluating oral gonadotropin releasing hormone (GnRH) receptor antagonist linzagolix for the treatment of heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). More...

OBSV - ObsEva SA Announces Completion of Patient Recruitment in PRIMROSE 1 Phase 3 Clinical Trial of Linzagolix for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Geneva, Switzerland and Boston, MA – July 8, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductiv...
Previous 10 Next 10